Alaya.bio

Alaya.bio is a preclinical-stage French biotechnology company developing novel in vivo CAR-T therapies. The company's core technology is a targeting polymeric nanoparticle designed to enhance the transduction efficiency of quiescent immune cells, such as T-cells and NK-cells, while preserving their naive and memory phenotypes. Its platform aims to enable both ex vivo and in vivo (in situ) cell engineering for advanced immunotherapies.